

Cipla Icatibant – Now the Only PBS Listed Brand of Icatibant

Cipla Australia is pleased to announce the availability and PBS listing of Cipla Icatibant (icatibant 30 mg/3 mL injection, 3 mL syringe). Cipla Icatibant is also approved by the USFDA.

Cipla Icatibant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older with C1-esterase-inhibitor deficiency.

About Hereditary Angioedema

Hereditary angioedema (C1-esterase inhibitor deficiency) is a rare autosomal dominant disorder due to absolute (Type I – majority of cases) or functional (Type II) deficiency of C1-esterase inhibitor (C1-INH).

About Cipla

Based in Melbourne, Cipla Australia has a vast pipeline of products that are supplied in Australia as well as in the US & EU. Millions of Australians have access to a Cipla manufactured product through our community pharmacy partners around Australia.

Our state-of-the-art manufacturing facilities are TGA approved as well as being USFDA (USA) and MHRA (UK) approved. Cipla Australia has over 200 registered formulations with TGA through partnerships with market leaders and on its own. The list of registered medicines includes OTC (Over the Counter), prescription and hospital medicines. We are also involved in helping Australians access medicines through the SAS (Special Access Scheme). Cipla has earned a name for maintaining world-class quality across all our manufacturing units, products and services. Globally, our patent filing includes drug substances, drug products, platform technologies, and medical devices.

Product Information

<https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-01601-1&d=202010181016933>

CMI

<https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-CMI-02096-1>

PBS Availability

Authority Required: <https://www.pbs.gov.au/medicine/item/1976B>

Cipla Australia Contact

Email address: mahesh.mohan@cipla.com

Mobile: 0403 701 178.

For Hospital Orders

Hospital Contact

Email address: sales@reach-pharma.com

Mobile: 0478 061 879